Proficio Capital Partners LLC Buys 10,000 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Proficio Capital Partners LLC boosted its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 100.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 20,000 shares of the company’s stock after buying an additional 10,000 shares during the period. Proficio Capital Partners LLC’s holdings in 4D Molecular Therapeutics were worth $111,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Marquette Asset Management LLC bought a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth approximately $116,000. Point72 Asset Management L.P. acquired a new stake in 4D Molecular Therapeutics during the 3rd quarter worth approximately $166,000. Y Intercept Hong Kong Ltd boosted its stake in 4D Molecular Therapeutics by 81.3% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,538 shares of the company’s stock valued at $265,000 after purchasing an additional 11,002 shares during the period. Intech Investment Management LLC acquired a new position in 4D Molecular Therapeutics in the 3rd quarter valued at $268,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in 4D Molecular Therapeutics during the 3rd quarter worth $295,000. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Trading Up 3.2 %

Shares of 4D Molecular Therapeutics stock opened at $4.24 on Thursday. The company has a market cap of $196.32 million, a PE ratio of -1.49 and a beta of 2.83. The company has a 50 day moving average of $4.97 and a 200-day moving average of $8.00. 4D Molecular Therapeutics, Inc. has a 1-year low of $3.73 and a 1-year high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10). Research analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Leerink Partners reduced their target price on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. Royal Bank of Canada decreased their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. Morgan Stanley lowered their target price on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. Finally, Bank of America cut their price target on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a research note on Monday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $30.63.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.